Results 211 to 220 of about 187,044 (318)

Pharmacodynamic optimization of β-lactams in the patient care setting [PDF]

, 2008
David P. Nicolau
openalex   +1 more source

Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to estimate the risk of gastrointestinal bleeding (GIB) by selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) individual agents. Methods A systematic review was conducted for each unique antidepressant (i.e.
Ainhoa Gomez‐Lumbreras, Abdelrahman G. Tawfik, Guilherme Del Fiol, Kensaku Kawamoto, Thomas Reese, Katy Trinkley, Aubrey Jones, James Mitchell, Daniel C. Malone   +8 more
wiley   +1 more source

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin-S Inhibitor, in Healthy Adult Subjects. [PDF]

Clin Transl Sci
Kojima T, Chen W, Smulders R, Stanhope S, Kowalski D, Heo N, Moy S, Goldston A, Han D, Zhu T.   +9 more
europepmc   +1 more source

Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet, Anna Largajolli, Petra M. Jauslin, Emilie Schindler, Mourad Hamimed, Wannee Kantasiripitak, Antonio Gonçalves, Eline Van Maanen, Khaled Benkali, Tomohisa Saito, Jonathan I. Silverberg, Andreas Wollenberg, Michael Graeber, Liliana Ulianov, Christophe Piketty, Luca Loprete, Vincent Duval, Nathalie Wagner   +17 more
wiley   +1 more source

Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review [PDF]

, 2019
Ioannis Loisios-Konstantinidis, Rafael Leal Monteiro Paraiso, Nikoletta Fotaki, Mark McAllister, Rodrigo Cristofoletti, Jennifer Dressman   +5 more
openalex   +1 more source

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

Tutorial Drug-Drug Interactions. [PDF]

Clin Transl Sci
Sellers EM.
europepmc   +1 more source

PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS IN PATIENTS WITH RENAL DYSFUNCTION

, 2017
К. Zakon, V. Dudarenko, М. Kolesnyk
openalex   +2 more sources

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics. [PDF]

J Pharmacokinet Pharmacodyn
Derbalah A, Stader F, Liu C, Zyla A, Abdulla T, Wu Q, Jamei M, Gardner I, Sepp A.   +8 more
europepmc   +1 more source